Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

NCT03811002 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

544

Enrollment

NIH

Sponsor class

Conditions

Limited Stage Lung Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8

Interventions

RADIATION: 3-Dimensional Conformal Radiation Therapy
DRUG: Atezolizumab
PROCEDURE: Biospecimen Collection
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Etoposide
RADIATION: Intensity-Modulated Radiation Therapy
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]